Fire Fight: Smothering the Flame of Type 2 Inflammation—Advances in Understanding and Managing Type 2 Inflammatory Diseases

Activity Details

Provided By

This activity is jointly provided by Global Education Group and RMEI Medical Education, LLC.

Target Audience

The educational design of this activity addresses the needs of physicians who specialize in allergy/immunology, dermatology, otolaryngology, pulmonology, and primary care.

Learning Objectives

After completing this activity, the participant should be better able to:

• Describe the role of the type 2 inflammatory cascade in the underlying pathophysiology of atopic diseases
• Identify patients with type 2 inflammatory diseases who are eligible for step-up therapies, including new and emerging biologics

Activity Description

In this interactive panel discussion, 3 multidisciplinary clinical opinion leaders discuss type 2 Inflammation as an underlying cause of asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps, with implications for therapeutic choices in patient care.

Statement of Educational Need

Advances in understanding the pathophysiology of atopic diseases highlight the importance and commonality of underlying type 2 inflammation in a range of diseases like asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps. Key drivers of type 2 inflammation have been identified, with IL-4 and IL-13 playing a central role. In the last few years, biologics targeting type 2 inflammation have emerged as effective treatment options for patients with atopic diseases, particularly in people with moderate-to-severe disease. Because of the relative novelty of these treatments, healthcare professionals should be aware of the pathophysiology of disease, as well as the efficacy, safety, and tolerability of biologics, the rationale for use, and how to incorporate these treatments into management of appropriate patients. 

Faculty

Peter A. Lio, MD, FAAD
Clinical Assistant Professor, Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL

Peter A. Lio, MD, FAAD, is a clinical assistant professor of dermatology & pediatrics at Northwestern University Feinberg School of Medicine in Chicago, IL. Dr Lio received his medical degree from Harvard Medical School in Boston, MA, completed his internship in pediatrics at Boston Children’s Hospital and his residency in dermatology at Harvard University/Massachusetts General Hospital, where he served as the chief resident in dermatology. While at Harvard, he received formal training in acupuncture. Dr Lio is board certified in dermatology.

Dr Lio’s interests are in atopic dermatitis and connective tissue diseases, such as lupus and dermatomyositis. As a medical acupuncturist, his interests are in alternative medical approaches to dermatologic diseases.

Dr Lio is the founding director of the Chicago Integrative Eczema Center and a founding partner of Medical Dermatology Associates of Chicago. He currently serves as a board member and scientific advisory committee member for the National Eczema Association; a member of the American Academy of Dermatology’s Atopic Dermatitis Expert Resource Group; and is a founding faculty member of the Integrative Dermatology Certificate Program. Dr Lio has over 150 publications and 3 textbooks.

Joseph K. Han, MD
Professor, EVMS
Chief, Division of Rhinology and Endoscopic Sinus-Skull Base Surgery
Chief, Division of Allergy
President Elect, ARS
Chair Elect, AAAAI, RROAC
Eastern Virginia Medical School
Norfolk, VA

Joseph K. Han, MD, is a professor in the Department of Otolaryngology & Head and Neck Surgery at Eastern Virginia Medical School and is the chief for the Division of Rhinology & Endoscopic Sinus and Skull Base Surgery. He is also the chief for the Division of Allergy. Dr Han received his medical degree from the Medical College of Pennsylvania and completed an otolaryngology-head & neck surgery residency at the Medical College of Wisconsin. He completed a fellowship in rhinology and allergy at Oregon Health Sciences University. Dr Han is board certified in otolaryngology - head & neck surgery.

Dr Han is very active in both basic science research and clinical research studies. He has been awarded NIH funding for the study of chronic sinusitis and has been the lead investigator for several multi-national, multi-institutional, prospective clinical trials on chronic sinusitis, and nasal polyposis.

Dr Han has served in many societies, including serving as the president for the Virginia Society of Otolaryngology, the Tidewater Otolaryngology & Ophthalmology Society, and the Korean American Otolaryngology Society, and as Chair of the Rhinology and Paranasal Sinus Committee within the American Academy of Otolaryngology & Head and Neck Surgery. Dr Han is currently the President Elect for the American Rhinologic Society and will be the President in the fall of 2020. He is one of the few physicians who is a fellow of the ARS, AAAAI, and AAOA.

Dr Han is an Associate Editor and on the Editorial Board for the International Forum of Allergy and Rhinology and is currently a guest examiner for the American Board of Otolaryngology & Head and Neck Surgery. He has over 94 scientific publications, over 157 national and international scientific presentations, and over 148 guest lectureships.

Anju T. Peters, MD, MS
Professor, Medicine
Division of Allergy-Immunology
Director, Clinical Research
Northwestern University Feinberg School of Medicine
Chicago, IL

Anju T. Peters, MD, MS, is a professor in the Department of Medicine at Northwestern University Feinberg School of Medicine in Chicago, IL. Dr Peters graduated from the University of Michigan Medical School and completed her residency and fellowship in the division of allergy-immunology at Northwestern University Feinberg School of Medicine. She currently serves as the director of clinical research in the Division of Allergy-Immunology at Northwestern University Feinberg School of Medicine. She practices as an allergist in the Division of Allergy-Immunology and in the Sinus and Allergy Center of Northwestern University. Dr Peters is board certified in allergy and immunology.

Dr Peters has specific interest in taking care of patients with chronic rhinosinusitis, with and without nasal polyps, and associated conditions of asthma and immunodeficiencies. She has focused her research in the field of chronic rhinosinusitis and its associated comorbidities, including allergic rhinitis, asthma, and immunodeficiencies.

Dr Peters has published extensively in these areas and is currently involved in clinical trials in asthma and chronic rhinosinusitis. She is the current chair of the AAAAI/ACAAI Joint Task Force practice parameters on chronic rhinosinusitis, which are leading guidelines on the treatment of chronic rhinosinusitis. In addition to her work on the national practice guidelines in the field of rhinosinusitis, Dr Peters has been invited to present original clinical research and lectures at local, national, and international meetings.

Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Peter Lio, MD, FAAD
Consultant/Independent Contractor: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche Posay/L’Oreal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre-Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, YoubeeCare (Stock Options).
Grant/Research Support: AbbVie, National Eczema Association, Regeneron/Sanofi Genzyme.
Honoraria: AbbVie, Amyris, AObiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche Posay/L’Oreal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre-Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, YobeeCare (Stock Options).
Speaker’s Bureau: Galderma, L’Oreal, Pfizer, Regeneron/Sanofi Genzyme.
Advisory Board: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche Posay/L’Oreal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre-Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, YobeeCare (Stock Options).
Stock Shareholder: Altus Labs, Micreos, YoBee.
Other Royalty: Theraplex AIM (OTC product) Royalties. 

Joseph K. Han, MD
Consultant/Independent Contractor: AstraZeneca, Genentech, GlaxoSmithKline, Novartis, Sanofi Regeneron.

Anju Peters, MD, MS
Grant/Research Support: AstraZeneca, Optinose (Research Support is to Institution)
Advisory Board: AstraZeneca, GlaxoSmithKline, Optinose, Sanofi Regeneron.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Lindsay Borvansky has nothing to disclose.
Andrea Funk has nothing to disclose.
Liddy Knight has nothing to disclose.
Ashley Cann has nothing to disclose.
Deborah Liao has nothing to disclose.
Sharon Powell has nothing to disclose.
Elizabeth Johnson has nothing to disclose. 

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and RMEI Medical Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians. 

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

There is no fee for this educational activity. 

This activity was released on November 23, 2020 and is valid for one year. Requests for credit must be made no later than November 23, 2021.

In order to receive credit for this activity, the participant must:

• Read the learning objectives and faculty disclosures.
• Participate in the activity
• Complete the activity post-test (score 75% or higher) and evaluation.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals. 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and RMEI Medical Education, LLC do not recommend the use of any agent outside of the labeled indications.   

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Contact Information for Questions About the Activity

For information about the accreditation of this program, please contact Global Education Group at 303-395-1782 or cme@globaleducationgroup.com. 

Fire Fight: Smothering the Flame of Type 2 Inflammation—Advances in Understanding and Managing Type 2 Inflammatory Diseases

Activity Details

Provided By

This activity is jointly provided by Global Education Group and RMEI Medical Education, LLC.

Target Audience

The educational design of this activity addresses the needs of physicians who specialize in allergy/immunology, dermatology, otolaryngology, pulmonology, and primary care.

Learning Objectives

After completing this activity, the participant should be better able to:

• Describe the role of the type 2 inflammatory cascade in the underlying pathophysiology of atopic diseases
• Identify patients with type 2 inflammatory diseases who are eligible for step-up therapies, including new and emerging biologics

Activity Description

In this interactive panel discussion, 3 multidisciplinary clinical opinion leaders discuss type 2 Inflammation as an underlying cause of asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps, with implications for therapeutic choices in patient care.

Statement of Educational Need

Advances in understanding the pathophysiology of atopic diseases highlight the importance and commonality of underlying type 2 inflammation in a range of diseases like asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps. Key drivers of type 2 inflammation have been identified, with IL-4 and IL-13 playing a central role. In the last few years, biologics targeting type 2 inflammation have emerged as effective treatment options for patients with atopic diseases, particularly in people with moderate-to-severe disease. Because of the relative novelty of these treatments, healthcare professionals should be aware of the pathophysiology of disease, as well as the efficacy, safety, and tolerability of biologics, the rationale for use, and how to incorporate these treatments into management of appropriate patients. 

Faculty

Peter A. Lio, MD, FAAD
Clinical Assistant Professor, Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL

Peter A. Lio, MD, FAAD, is a clinical assistant professor of dermatology & pediatrics at Northwestern University Feinberg School of Medicine in Chicago, IL. Dr Lio received his medical degree from Harvard Medical School in Boston, MA, completed his internship in pediatrics at Boston Children’s Hospital and his residency in dermatology at Harvard University/Massachusetts General Hospital, where he served as the chief resident in dermatology. While at Harvard, he received formal training in acupuncture. Dr Lio is board certified in dermatology.

Dr Lio’s interests are in atopic dermatitis and connective tissue diseases, such as lupus and dermatomyositis. As a medical acupuncturist, his interests are in alternative medical approaches to dermatologic diseases.

Dr Lio is the founding director of the Chicago Integrative Eczema Center and a founding partner of Medical Dermatology Associates of Chicago. He currently serves as a board member and scientific advisory committee member for the National Eczema Association; a member of the American Academy of Dermatology’s Atopic Dermatitis Expert Resource Group; and is a founding faculty member of the Integrative Dermatology Certificate Program. Dr Lio has over 150 publications and 3 textbooks.

Joseph K. Han, MD
Professor, EVMS
Chief, Division of Rhinology and Endoscopic Sinus-Skull Base Surgery
Chief, Division of Allergy
President Elect, ARS
Chair Elect, AAAAI, RROAC
Eastern Virginia Medical School
Norfolk, VA

Joseph K. Han, MD, is a professor in the Department of Otolaryngology & Head and Neck Surgery at Eastern Virginia Medical School and is the chief for the Division of Rhinology & Endoscopic Sinus and Skull Base Surgery. He is also the chief for the Division of Allergy. Dr Han received his medical degree from the Medical College of Pennsylvania and completed an otolaryngology-head & neck surgery residency at the Medical College of Wisconsin. He completed a fellowship in rhinology and allergy at Oregon Health Sciences University. Dr Han is board certified in otolaryngology - head & neck surgery.

Dr Han is very active in both basic science research and clinical research studies. He has been awarded NIH funding for the study of chronic sinusitis and has been the lead investigator for several multi-national, multi-institutional, prospective clinical trials on chronic sinusitis, and nasal polyposis.

Dr Han has served in many societies, including serving as the president for the Virginia Society of Otolaryngology, the Tidewater Otolaryngology & Ophthalmology Society, and the Korean American Otolaryngology Society, and as Chair of the Rhinology and Paranasal Sinus Committee within the American Academy of Otolaryngology & Head and Neck Surgery. Dr Han is currently the President Elect for the American Rhinologic Society and will be the President in the fall of 2020. He is one of the few physicians who is a fellow of the ARS, AAAAI, and AAOA.

Dr Han is an Associate Editor and on the Editorial Board for the International Forum of Allergy and Rhinology and is currently a guest examiner for the American Board of Otolaryngology & Head and Neck Surgery. He has over 94 scientific publications, over 157 national and international scientific presentations, and over 148 guest lectureships.

Anju T. Peters, MD, MS
Professor, Medicine
Division of Allergy-Immunology
Director, Clinical Research
Northwestern University Feinberg School of Medicine
Chicago, IL

Anju T. Peters, MD, MS, is a professor in the Department of Medicine at Northwestern University Feinberg School of Medicine in Chicago, IL. Dr Peters graduated from the University of Michigan Medical School and completed her residency and fellowship in the division of allergy-immunology at Northwestern University Feinberg School of Medicine. She currently serves as the director of clinical research in the Division of Allergy-Immunology at Northwestern University Feinberg School of Medicine. She practices as an allergist in the Division of Allergy-Immunology and in the Sinus and Allergy Center of Northwestern University. Dr Peters is board certified in allergy and immunology.

Dr Peters has specific interest in taking care of patients with chronic rhinosinusitis, with and without nasal polyps, and associated conditions of asthma and immunodeficiencies. She has focused her research in the field of chronic rhinosinusitis and its associated comorbidities, including allergic rhinitis, asthma, and immunodeficiencies.

Dr Peters has published extensively in these areas and is currently involved in clinical trials in asthma and chronic rhinosinusitis. She is the current chair of the AAAAI/ACAAI Joint Task Force practice parameters on chronic rhinosinusitis, which are leading guidelines on the treatment of chronic rhinosinusitis. In addition to her work on the national practice guidelines in the field of rhinosinusitis, Dr Peters has been invited to present original clinical research and lectures at local, national, and international meetings.

Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Peter Lio, MD, FAAD
Consultant/Independent Contractor: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche Posay/L’Oreal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre-Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, YoubeeCare (Stock Options).
Grant/Research Support: AbbVie, National Eczema Association, Regeneron/Sanofi Genzyme.
Honoraria: AbbVie, Amyris, AObiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche Posay/L’Oreal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre-Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, YobeeCare (Stock Options).
Speaker’s Bureau: Galderma, L’Oreal, Pfizer, Regeneron/Sanofi Genzyme.
Advisory Board: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche Posay/L’Oreal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre-Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, YobeeCare (Stock Options).
Stock Shareholder: Altus Labs, Micreos, YoBee.
Other Royalty: Theraplex AIM (OTC product) Royalties. 

Joseph K. Han, MD
Consultant/Independent Contractor: AstraZeneca, Genentech, GlaxoSmithKline, Novartis, Sanofi Regeneron.

Anju Peters, MD, MS
Grant/Research Support: AstraZeneca, Optinose (Research Support is to Institution)
Advisory Board: AstraZeneca, GlaxoSmithKline, Optinose, Sanofi Regeneron.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Lindsay Borvansky has nothing to disclose.
Andrea Funk has nothing to disclose.
Liddy Knight has nothing to disclose.
Ashley Cann has nothing to disclose.
Deborah Liao has nothing to disclose.
Sharon Powell has nothing to disclose.
Elizabeth Johnson has nothing to disclose. 

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and RMEI Medical Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians. 

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

There is no fee for this educational activity. 

This activity was released on November 23, 2020 and is valid for one year. Requests for credit must be made no later than November 23, 2021.

In order to receive credit for this activity, the participant must:

• Read the learning objectives and faculty disclosures.
• Participate in the activity
• Complete the activity post-test (score 75% or higher) and evaluation.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals. 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and RMEI Medical Education, LLC do not recommend the use of any agent outside of the labeled indications.   

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Contact Information for Questions About the Activity

For information about the accreditation of this program, please contact Global Education Group at 303-395-1782 or cme@globaleducationgroup.com. 

Activity Details

Accredited By

Target Audience

This activity will target neurologists, pediatricians, and geneticists, as well as other health care providers who may be involved in the management of patients with SMA.

Learning Objectives

• Describe criteria for SMA diagnosis
• Describe how SMA diagnosis can be missed or delayed

Activity Description

This education focuses on the early diagnosis and treatment of SMA and the importance of newborn screening. Pre-symptomatic treatment of SMA can dramatically change the disease course and newborn screening is crucial to early detection and early treatment.

Statement of Educational Need

The rapid influx of information surrounding emerging treatments for SMA means that there are critical gaps in clinician knowledge and the ability to apply it in practice, creating a need for education to support clinicians who recognize, diagnose, and/or manage patients with SMA.

Faculty

Sharon Aharoni, MD
Director of SMA Therapies,
Schneider Institute of Child Neurology Children’s Medical Center
Petach Tikva, Israel

Sharon Aharoni, MD, has participated in contract research for AveXis.

Professor Enrico Bertini
Unit of Neuromuscular and Neurodegenerative Disorders
Laboratory of Molecular Medicine
Bambino Gesu' Children's Research Hospital
Rome, Italy

Professor Enrico Bertini has no financial relationships to disclose.

Professor Aviva Fattal-Valevski
Director, Pediatric Neurology Institute
Dana Children's Hospital, Tel Aviv Medical Center
Tel Aviv, Israel

Professor Aviva Fattal-Valevski has no financial relationships to disclose.

Professor Marcondes Cavalcante França Junior
Assistant Professor of Neurology
The University of Campinas
Sao Paulo, Brazil

Professor Marcondes Cavalcante França Junior has participated in advisory boards for AveXis, Biogen, and Roche.

Professor Wolfgang Mueller-Felber
Head of Center for Pediatric Neuromuscular Disorders
and Clinical Neurophysiology
Dr. von Hauner Children’s Hospital
Munich, Germany

Professor Wolfgang Mueller-Felber has participated in scientific advisory boards for Genzyme and has received research support from GlaxoSmithKline, Lilly, and Trophos.

J. Andoni Urtizberea, MD, MSc
Attending Physician
Institut de Myologie
Paris, France

J. Andoni Urtizberea, MD, MSc, has no financial relationships to disclose.

Conflict of Interest Policy/Disclosure Statement

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Accreditation Statement

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Physicians
The France Foundation designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The France Foundation, an ACCME accredited provider.

Method of Participation/How to Receive Credit

• There are no fees for participating in and receiving credit for this activity.
• Review the activity objectives and CME/CE information.
• Complete the CME/CE activity.
• Complete the online posttest. A score of 100% is required to complete this activity. The participant may take the test until successfully passed.
• Complete the CME/CE evaluation/attestation form. The form provides each participant the opportunity to comment on how the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
• Credit documentation/reporting:
• • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.

Statement of Commercial Support

This activity is supported by an educational grant from AveXis.

Disclaimer Statement/Disclosure of Unlabeled Use

The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of their recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.

Contact Information for Questions About the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Activity Details

Accredited By

Target Audience

This activity will target neurologists, pediatricians, and geneticists, as well as other health care providers who may be involved in the management of patients with SMA.

Learning Objectives

• Describe criteria for SMA diagnosis
• Describe how SMA diagnosis can be missed or delayed

Activity Description

This education focuses on the early diagnosis and treatment of SMA and the importance of newborn screening. Pre-symptomatic treatment of SMA can dramatically change the disease course and newborn screening is crucial to early detection and early treatment.

Statement of Educational Need

The rapid influx of information surrounding emerging treatments for SMA means that there are critical gaps in clinician knowledge and the ability to apply it in practice, creating a need for education to support clinicians who recognize, diagnose, and/or manage patients with SMA.

Faculty

Sharon Aharoni, MD
Director of SMA Therapies,
Schneider Institute of Child Neurology Children’s Medical Center
Petach Tikva, Israel

Sharon Aharoni, MD, has participated in contract research for AveXis.

Professor Enrico Bertini
Unit of Neuromuscular and Neurodegenerative Disorders
Laboratory of Molecular Medicine
Bambino Gesu' Children's Research Hospital
Rome, Italy

Professor Enrico Bertini has no financial relationships to disclose.

Professor Aviva Fattal-Valevski
Director, Pediatric Neurology Institute
Dana Children's Hospital, Tel Aviv Medical Center
Tel Aviv, Israel

Professor Aviva Fattal-Valevski has no financial relationships to disclose.

Professor Marcondes Cavalcante França Junior
Assistant Professor of Neurology
The University of Campinas
Sao Paulo, Brazil

Professor Marcondes Cavalcante França Junior has participated in advisory boards for AveXis, Biogen, and Roche.

Professor Wolfgang Mueller-Felber
Head of Center for Pediatric Neuromuscular Disorders
and Clinical Neurophysiology
Dr. von Hauner Children’s Hospital
Munich, Germany

Professor Wolfgang Mueller-Felber has participated in scientific advisory boards for Genzyme and has received research support from GlaxoSmithKline, Lilly, and Trophos.

J. Andoni Urtizberea, MD, MSc
Attending Physician
Institut de Myologie
Paris, France

J. Andoni Urtizberea, MD, MSc, has no financial relationships to disclose.

Conflict of Interest Policy/Disclosure Statement

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Accreditation Statement

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Physicians
The France Foundation designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The France Foundation, an ACCME accredited provider.

Method of Participation/How to Receive Credit

• There are no fees for participating in and receiving credit for this activity.
• Review the activity objectives and CME/CE information.
• Complete the CME/CE activity.
• Complete the online posttest. A score of 100% is required to complete this activity. The participant may take the test until successfully passed.
• Complete the CME/CE evaluation/attestation form. The form provides each participant the opportunity to comment on how the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
• Credit documentation/reporting:
• • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.

Statement of Commercial Support

This activity is supported by an educational grant from AveXis.

Disclaimer Statement/Disclosure of Unlabeled Use

The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of their recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.

Contact Information for Questions About the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Activity Details

Accredited By

Target Audience

This educational initiative has been designed for allergists, pulmonologists, fellows, and internal medicine physicians involved in the management of patients with severe asthma.

Learning Objectives

• Demonstrate the ability to diagnose patients with severe versus difficult-to-treat versus persistent uncontrolled asthma
• Describe the risks of OCS overuse and summarize strategies to reduce OCS use in severe asthma
• Employ biomarker testing in the evaluation of severe asthma and utilize results to classify patients with severe asthma
• Develop personalized treatment plans for patients with severe asthma that are consistent with current evidence-based recommendations

Activity Description

Interactive Puzzle Activity

Statement of Educational Need

Severe asthma remains a disease with a high economic, healthcare, and patient burden. Patients with severe asthma suffer frequent exacerbations and the unpredictability of their disease. Prior to the availability of newer therapies that provide an opportunity to improve the management of patients with severe asthma, many patients relied on oral corticosteroids (OCS) as a mainstay of treatment. In fact, Cataldo et al. reported in 2020 that many patients with severe asthma were self-medicating with OCS during episodes of worsening symptoms or as prevention of such episodes in addition to physician-diagnosed exacerbation management. The utility of new therapies is underscored by the need for clinicians to be competent to make an efficient and accurate diagnosis and classification of severe asthma, to possess knowledge of recently released guidelines for severe asthma management, and to be able to select appropriate individualized therapy based on patient profiles and desires. This program has been designed to ensure that fellows and post-specialty-trained clinicians are able to meet the needs of the diverse population of severe asthma patients and design effective treatment plans to reduce symptoms, exacerbations, and the continued need for OCS in patients with severe asthma. 

Faculty

Reynold A. Panettieri, Jr., MD
Professor of Medicine
Robert Wood Johnson Medical School
Vice Chancellor, Clinical & Translational Science
Director, Rutgers Institute for Translational Medicine & Science
New Brunswick, New Jersey
Emeritus Professor of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Reynold A. Panettieri, Jr., MD​
Consulting Fees: AstraZeneca, MedImmune, RIFM, Equillium, Theravance
Speakers’ Bureaus: AstraZeneca, Sanofi, Genentech
Contracted Research: AstraZeneca, MedImmune, RIFM, Genentech, OncoArendi

Patima Tanapat, PhD, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of July 22, 2020 through July 22, 2021, participants must:

• Read the learning objectives and faculty disclosures
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Sanofi Genzyme and Regeneron Pharmaceuticals do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.

Contact Information for Questions About the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or info@integrityce.com.

Statement of Commercial Support

Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Activity Details

Accredited By

Target Audience

This educational initiative has been designed for allergists, pulmonologists, fellows, and internal medicine physicians involved in the management of patients with severe asthma.

Learning Objectives

• Demonstrate the ability to diagnose patients with severe versus difficult-to-treat versus persistent uncontrolled asthma
• Describe the risks of OCS overuse and summarize strategies to reduce OCS use in severe asthma
• Employ biomarker testing in the evaluation of severe asthma and utilize results to classify patients with severe asthma
• Develop personalized treatment plans for patients with severe asthma that are consistent with current evidence-based recommendations

Activity Description

Interactive Puzzle Activity

Statement of Educational Need

Severe asthma remains a disease with a high economic, healthcare, and patient burden. Patients with severe asthma suffer frequent exacerbations and the unpredictability of their disease. Prior to the availability of newer therapies that provide an opportunity to improve the management of patients with severe asthma, many patients relied on oral corticosteroids (OCS) as a mainstay of treatment. In fact, Cataldo et al. reported in 2020 that many patients with severe asthma were self-medicating with OCS during episodes of worsening symptoms or as prevention of such episodes in addition to physician-diagnosed exacerbation management. The utility of new therapies is underscored by the need for clinicians to be competent to make an efficient and accurate diagnosis and classification of severe asthma, to possess knowledge of recently released guidelines for severe asthma management, and to be able to select appropriate individualized therapy based on patient profiles and desires. This program has been designed to ensure that fellows and post-specialty-trained clinicians are able to meet the needs of the diverse population of severe asthma patients and design effective treatment plans to reduce symptoms, exacerbations, and the continued need for OCS in patients with severe asthma. 

Faculty

Reynold A. Panettieri, Jr., MD
Professor of Medicine
Robert Wood Johnson Medical School
Vice Chancellor, Clinical & Translational Science
Director, Rutgers Institute for Translational Medicine & Science
New Brunswick, New Jersey
Emeritus Professor of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Reynold A. Panettieri, Jr., MD​
Consulting Fees: AstraZeneca, MedImmune, RIFM, Equillium, Theravance
Speakers’ Bureaus: AstraZeneca, Sanofi, Genentech
Contracted Research: AstraZeneca, MedImmune, RIFM, Genentech, OncoArendi

Patima Tanapat, PhD, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of July 22, 2020 through July 22, 2021, participants must:

• Read the learning objectives and faculty disclosures
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Sanofi Genzyme and Regeneron Pharmaceuticals do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.

Contact Information for Questions About the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or info@integrityce.com.

Statement of Commercial Support

Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.